Current Research Studies

Cancer – ADVL1515: Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors

Condition or Therapy:

Solid tumors, CNS tumors, intrinsic brain stem tumors, optic pathway gliomas, pineal and elevations of CSF or serum tumor


Cancer and Bloor Disorders
Study Number: ADVL1515

What is the goal of this study?

This phase 1 trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are between 12 months and 21 years old
  • Have a recurrent or refractory solid tumor

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Julie Park